US Bancorp DE Acquires 2,268 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

US Bancorp DE boosted its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 22.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,430 shares of the biopharmaceutical company’s stock after purchasing an additional 2,268 shares during the period. US Bancorp DE’s holdings in Sage Therapeutics were worth $67,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Ieq Capital LLC bought a new position in shares of Sage Therapeutics during the 4th quarter worth approximately $57,000. Empowered Funds LLC acquired a new stake in shares of Sage Therapeutics in the 4th quarter valued at $91,000. Inspire Investing LLC grew its holdings in shares of Sage Therapeutics by 30.4% in the 4th quarter. Inspire Investing LLC now owns 75,313 shares of the biopharmaceutical company’s stock worth $409,000 after purchasing an additional 17,541 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Sage Therapeutics by 57.7% during the 4th quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 8,228 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Sage Therapeutics by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock valued at $8,975,000 after purchasing an additional 3,757 shares during the last quarter. 99.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Scotiabank dropped their price objective on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating for the company in a report on Wednesday, February 12th. Stifel Nicolaus dropped their price target on Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating for the company in a report on Monday, December 16th. TD Cowen reduced their price objective on Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating on the stock in a research note on Thursday, November 21st. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Finally, Bank of America started coverage on shares of Sage Therapeutics in a research report on Tuesday, March 11th. They set an “underperform” rating and a $5.00 price target on the stock. Three research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $8.81.

Sage Therapeutics Trading Up 3.9 %

NASDAQ:SAGE opened at $8.02 on Tuesday. The firm has a market capitalization of $493.08 million, a price-to-earnings ratio of -1.22 and a beta of 0.82. Sage Therapeutics, Inc. has a 1-year low of $4.62 and a 1-year high of $20.32. The business’s 50-day moving average price is $7.18 and its two-hundred day moving average price is $6.70.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. Sell-side analysts predict that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current year.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.